Topic:

Influenza

Latest Headlines

Latest Headlines

GlaxoSmithKline launched new e-commerce platform for vaccines, pharma products

In March, GlaxoSmithKline and Novartis completed their $7.1 billion asset swap that was nearly a year in the making. The deal saw the British pharma bolster its vaccine business as it traded away its oncology unit for Novartis' vaccines business. Now, Glaxo is officially announcing the launch of GSKDirect, a new e-commerce platform that simplifies the way customers order vaccines and pharmaceutical products from the company.

NIAID combines MedImmune, Sanofi H7N9 jabs into promising prime-boost vaccine

While H7N9 avian flu does not seem to move easily from person to person, the WHO notes that most people who catch it become severely ill. Several candidates for H7N9 pandemic flu have proven safe and immunogenic in clinical trials, but experts recommend that these be beefed up for practical use either via multiple doses or using an adjuvant. The National Institute of Allergy and Infectious Diseases reported Thursday that a team of scientists has successfully tested a prime-boost vaccine for the flu strain in a small clinical trial.

FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine

The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis shot that is now owned by CSL's Seqirus unit.

WHO meeting could change strain selection for flu vaccines

Health officials and experts will discuss ways to improve global surveillance of the flu and expedite the selection process for which flu strains to include in the vaccine each year.

CSL to buy back $723M of its shares

Australia's CSL, which completed its acquisition of Novartis' flu vaccines business this year, has launched a AU$1 million share buyback.

BARDA provides funding to Vaxart, U. of Cambridge for flu vaccine improvements

As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.

Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs

Older adults don't have as robust an immune response to the flu vaccine as young people do. So Sanofi Pasteur formulated a higher-dose version of its trivalent Fluzone vaccine, which was found in an economic analysis to result in lower medical costs for older adults.

FluGen reels in $12M to fund PhI of its universal flu jab

A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.

J&J, Scripps Research Institute test 'universal' flu vaccine in mice, monkeys

The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.

FluGen raises $12M round for universal flu vaccine

Madison, WI-based FluGen has raised a $12 million Series A from Venture Investors LLC, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board as well as existing investors led by Knox LLC. The money will fund the first human studies of REDEE FLU, a universal flu vaccine candidate.